Drug intelligence / Profile preview

CD19 iCAR-NK

Development stage: Phase 1
Lead developer: Allife Medical Science and Technology
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CD19 iCAR-NK is an induced pluripotent stem cell (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy being developed by All Life Biotechnology. The product consists of NK cells derived from a master iPSC line, which are genetically engineered to express a CAR targeting the CD19 antigen. This approach is designed to treat CD19-positive B-lineage malignancies, such as leukemia, by leveraging the innate anti-tumor activity of NK cells combined with the specificity of the CAR. The use of iPSCs allows for the production of a standardized, off-the-shelf therapeutic product, potentially reducing costs and improving accessibility compared to autologous CAR-T cell therapies. It is currently in Phase 1 clinical development.

Other names: CD19 iPSC-derived CAR-NKCD-19 iPSC-derived CAR-NKCD 19 iPSC-derived CAR-NK

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CD19 iCAR-NK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD19 iCAR-NK.

Explore the full profile